You are not logged in.
This means
you CAN ONLY VIEW reports that were published prior to Wednesday, March 13, 2024.
You
MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.
 MIDDAY BREAKOUTS REPORT - FRIDAY, JULY 8TH, 2022
Previous Mid Day Report Next Mid Day Report >>>
|
|
DOW 31395.59 11.04 (0.04%) | NASDAQ 11660.28 38.94 (0.34%) | S&P 500 3908.82 6.2 (0.16%)
|
Time of Screening :
7/8/2022 12:22:36 PM Report Released :
7/8/2022 12:52:06 PM
Price is:
Above 52W High and Less Than 52W High
but within 15% of the 52 Week High
Volume Is:
At least 40% of 50 Day Average at
the time of the screening.
More details about this report...
At around
mid-way through each trading day we run
a screen against our database of
high-ranked stocks, searching for
possible buy candidates that are trading
at or near their 52-week high on above
average volume. The results of that
screen are split into the two sections
you see below. The first, titled
"TODAY's FEATURED STOCKS" shows stocks
that our experts have recently
identified as among the strongest candidates to
consider. Stocks highlighted in yellow
are the most timely and noteworthy, so
particular attention and prompt action
may be appropriate. The second section,
titled "TODAY's BREAKOUT SCREEN" shows
the remainder of stocks meeting today's
screen parameters. Our experts have
reviewed and included notes on these
stocks as well, but found that they may
not match up as favorably.
|
|
Y - Today's strongest
candidates
highlighted
by our staff
of experts.
|
|
G - Previously featured in
this report as yellow and
now may no longer be buyable
under the guidelines.
|
|
|
Symbol/Exchange
Company Name
Industry Group |
PRICE |
CHANGE
(%Change) |
Day High |
Volume
(% DAV)
(50 DAV) |
52 Wk Hi
% From Hi |
Date
Featured |
Price
Featured |
Pivot Point |
|
Max Buy |
CI
- NYSE
Cigna Corp
|
$279.14
|
+3.36
1.22%
|
$281.49
|
1,050,430
59.28% of 50 DAV
50 DAV is 1,772,000
|
$273.58
2.03%
|
7/7/2022 |
$276.55
|
PP = $273.68
MB = $287.36 |
Most Recent Note - 7/8/2022 12:24:26 PM
Y - Hitting another new all-time high today while on track for a 3rd consecutive volume-driven gain. Finished strong after highlighted in yellow in the prior mid-day report with new pivot point based on its 5/31/22 high plus 10 cents. The volume-driven gain triggered a technical buy signal. Rebound above its 50 DMA line ($260) helped its outlook to improve since dropped from the Featured Stocks list on 6/13/22.
>>> The latest Featured Stock Update with an annotated graph appeared on 7/7/2022. Click here.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
HRMY
- NASDAQ
Harmony Biosciences Holdings
|
$54.18
|
-1.27
-2.29%
|
$55.20
|
286,811
54.84% of 50 DAV
50 DAV is 523,000
|
$55.60
-2.56%
|
7/6/2022 |
$54.12
|
PP = $52.85
MB = $55.49 |
Most Recent Note - 7/8/2022 12:32:59 PM
Y - Pulling back today following 4 consecutive gains marked by above average volume as it rallied to new highs and triggered a technical buy signal. Prior highs in the $52-54 area define initial support to watch on pullbacks. Reported strong sales revenues and earnings increases in quarterly comparisons through Mar '22 versus the year ago periods. Annual earnings history is limited. Completed its $24 IPO on 8/19/20.
>>> The latest Featured Stock Update with an annotated graph appeared on 7/6/2022. Click here.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
|
 |
Symbol - Exchange - Industry Group
Company Name |
Last |
Chg |
Day
High |
52 WK Hi |
% From Hi |
Volume
% DAV |
DAV |
CNC
- NYSE - HEALTH SERVICES - Health Care Plans
Centene Corp
|
$88.35 |
+3.09
3.62%
|
$88.77
|
$89.92
|
-1.75% |
2,128,224
70.87%
|
3,003,000
|
Most Recent Note for CNC - 7/8/2022 12:27:09 PM
Approaching its 52-week high with today's big gain. Rebounded impressively since finding prompt support near its 200 DMA line. Prior mid-day reports noted - "Reported earnings +12% on +24% sales revenues for the Mar '22 quarter versus the year ago period. Prior quarterly comparisons were not strong and steady above the +25% minimum earnings guideline (C criteria). Annual earnings history (A criteria) has been steady. Shares split 2:1 on 2/07/19 and also 2:1 back on 2/20/15. Completed a new Public Offering on 5/03/18."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
DGICA
- NASDAQ - Insurance-Prop/Cas/Titl
Donegal Group Inc Cl A
|
$16.84 |
+0.23
1.38%
|
$16.84
|
$17.13
|
-1.69% |
53,788
52.22%
|
103,000
|
Most Recent Note for DGICA - 7/8/2022 12:28:08 PM
Hovering near its 52-week high following volume-driven gains. Prior mid-day reports noted - "Reported earnings +48% on +5% sales revenues for the Mar '22 quarter versus the year ago period. Prior quarterly sales revenues and earnings growth has not been strong and steady. Annual earnings (A criteria) history also has been up and down."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
GSK
- NYSE - Medical-Diversified
Glaxosmithkline Plc Adr
|
$42.46 |
-0.86
-1.99%
|
$42.77
|
$46.97
|
-9.60% |
2,836,363
47.81%
|
5,933,000
|
Most Recent Note for GSK - 7/8/2022 12:29:56 PM
Sputtering below its 200 DMA line again after meeting resistance near its 50 DMA line. Prior mid-day reports noted - "UK-based pharmaceuticals firm's quarterly comparisons through Mar '22 have not shown strong and steady earnings increases above the +25% minimum guideline (C criteria). Annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
IBN
- NYSE - BANKING - Money Center Banks
Icici Bank Ltd Adr
|
$19.23 |
+0.18
0.92%
|
$19.27
|
$22.34
|
-13.94% |
4,398,338
51.33%
|
8,569,000
|
Most Recent Note for IBN - 7/8/2022 12:34:06 PM
This India-based bank's sales revenues and earnings have not shown strong or steady quarterly and annual growth or acceleration.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
MCK
- NYSE - WHOLESALE - Drugs Wholesale
Mckesson Corp
|
$331.57 |
+10.32
3.21%
|
$333.70
|
$339.94
|
-2.46% |
621,859
51.35%
|
1,211,000
|
Most Recent Note for MCK - 7/8/2022 12:37:06 PM
Rallying near its all-time high with today's big gain after an 8-week flat base while recently consolidating above its 50 DMA line. Some fundamental concerns remain since last noted in the 5/12/22 mid-day report - "Reported earnings +15% on +12% sales revenues for the Mar '22 quarter versus the year ago period, below the +25% minimum earnings guideline (C criteria). It has a steady annual earnings (A criteria) history."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
MNST
- NASDAQ - MEDIA - Advertising Agencies
Monster Beverage Corp
|
$96.44 |
-0.55
-0.57%
|
$97.80
|
$99.89
|
-3.45% |
1,374,682
43.93%
|
3,129,000
|
Most Recent Note for MNST - 7/8/2022 12:44:00 PM
Rebounded within striking distance of its 52-week and all-time highs with volume-driven gains this week. Fundamental concerns remain after it reported earnings -7% on +22% sales revenues for the Jun '22 quarter versus the year ago period, its 3rd consecutive comparison with weak earnings although sales revenues showed solid increases. Not a match with the fact-based investment system's fundamental guidelines calling for earnings increases of at least +25% (C criteria). The beverage firm is a past great winner with a very strong annual earnings (A criteria) history. Last noted with caution in the 10/01/20 mid-day report.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
NVO
- NYSE - DRUGS - Drug Manufacturers - Other
Novo Nordisk A/S Adr
|
$109.35 |
-0.59
-0.54%
|
$109.50
|
$122.16
|
-10.49% |
619,444
40.89%
|
1,515,000
|
Most Recent Note for NVO - 7/8/2022 12:46:38 PM
This Denmark-based Medical - Ethical Drug firm is consolidating near its 200 DMA line which has acted as support. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
RGP
- NASDAQ - Comml Svcs-Consulting
Resources Connection Inc
|
$21.01 |
-0.04
-0.17%
|
$21.22
|
$21.62
|
-2.81% |
100,251
40.92%
|
245,000
|
Most Recent Note for RGP - 7/8/2022 12:47:29 PM
Held its ground near its 52-week high after a noted "negative reversal" on 6/28/22. Feb '22 quarterly earnings rose +364% on +31% sales revenues versus the year ago period, its 3rd strong quarter after a considerable stretch of negative comparisons.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
SLP
- NASDAQ - COMPUTER SOFTWARE & SERVICES - Business Software & Services
Simulations Plus Inc
|
$54.40 |
-0.91
-1.65%
|
$56.23
|
$57.96
|
-6.14% |
45,975
40.69%
|
113,000
|
Most Recent Note for SLP - 7/8/2022 12:49:39 PM
Challenged its 52-week high on the prior session with its 6th consecutive volume-driven gain, however, it faces resistance due to overhead supply up to the $90 level. Prior mid-day report cautioned members - "Reported earnings +11% on +17% sales revenues for the May '22 quarter versus the year-ago period and fundamental concerns remain. Prior quarterly comparisons were not strong and steady above the +25% minimum earnings guideline (C criteria). Quarterly sales revenues totals have been in the $9-15 million range, growing, but still rather minuscule for publicly traded companies. Has a new CEO effective 6/26/18."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
VIVO
- NASDAQ - DRUGS - Diagnostic Substances
Meridian Bioscience Inc
|
$33.07 |
-0.20
-0.60%
|
$33.44
|
$34.38
|
-3.81% |
2,089,284
452.23%
|
462,000
|
Most Recent Note for VIVO - 7/8/2022 12:51:57 PM
Perched near its 52-week high following volume-driven gains after M&A news this week. Prior mid-day reports cautioned members - "Quarterly earnings increases through Mar '22 versus the year ago periods have been below the +25% minimum guideline (C criteria). Up and down annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines. On 4/18/08 it was dropped from the Featured Stocks list."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
|
|
|
THESE ARE NOT BUY RECOMMENDATIONS!
Comments contained in the body of this report are technical
opinions only. The material herein has been obtained
from sources believed to be reliable and accurate, however,
its accuracy and completeness cannot be guaranteed.
We are not an investment advisor, hence it does
not endorse or recommend any securities or other investments.
Any recommendation contained in this report may not
be suitable for all investors and it is not to be deemed
an offer or solicitation on our part with respect to
the purchase or sale of any securities. All trademarks,
service marks and trade names appearing in this report
are the property of their respective owners, and are
likewise used for identification purposes only.
This report is a service available
only to active Paid Premium Members.
You may opt-out of receiving report notifications
at any time. Questions or comments may be submitted
by writing to FactBasedInvesting.com c/o Premium
Member Services 665 S.E. 10 Street, Suite 201
Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.
We appreciate any feedback
members may wish to send via the inquiry form
here.
|
|
|
